DUBLIN--(BUSINESS WIRE)--May 17, 2018--The "Global Respiratory Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.

Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.

Market Dynamics

Drivers

Increasing Aging Population Rising Prevalence Of Respiratory Diseases High Prevalence Of Tobacco Smoking

Opportunities

Supportive Initiatives From Government And Other Organizations Huge Pool Of Undiagnosed Chronic Obstructive Pulmonary Disease Population

Restraints

Expiry Of Patents For Blockbuster Drugs Complex Drug Development Process

Report Category:

Therapy Type

Asthma Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Cystic Fibrosis

End-user

Hospitals Ambulatory Care Others

Key Topics Covered:

1 Industry Outlook

2 Report Outline

3 Market Snapshot

4 Market Outline

5 Market Characteristics

6 Application: Market Size And Analysis

7 Regions: Market Size And Analysis

8 Competitive Landscape

9 Vendor Profiles

Novartis AG Glaxosmithkline Plc Astra Zenca Plc F.Hoffmann-La Roche Ltd. Vertex Pharmaceuticals Inc.

10 Companies To Watch For

Boehringer Ingelheim GmbH Teva Pharmaceutical Industries Ltd. Gilead Sciences Inc. Bayer AG Pfizer Inc. Bristol-Myers Squibb Co. Merck & Co. Sanofi Mallinckrodt Plc

For more information about this report visit https://www.researchandmarkets.com/research/z5jrj7/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180517005640/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/17/2018 07:24 AM/DISC: 05/17/2018 07:23 AM

http://www.businesswire.com/news/home/20180517005640/en